Note 11. Subsequent Events	9 Months Ended	12 Months Ended
Sep. 30, 2015	Dec. 31, 2014
Notes
Note 10. Subsequent Events	Note 11. Subsequent Events Between November 5 to November 9, 2015, 255,750 Shares were issued for services. On November 9, 2015 a claim was filed to the Tel Aviv, Israel court against the Company and its wholly owned subsidiary for payment of past due fees by its former counsel.	Note 7. Subsequent Events. During January 2015, the Company issued 750,000 restricted units each consisting of one share of common stock, par value $0.0001 ("Common Stock") and one warrant to purchase one additional share of Common Stock (the "Units") at a post-reverse price of US$0.40 per units. The sales were made without registration under the Securities Act of 1933, as amended (the "Act") in reliance upon the exemptions provided in Section 4(2) of the Act and Regulation S promulgated by the United States Securities and Exchange Commission (the "SEC") under the Act. On February 2, 2015, the Company entered into a Loan Agreement with Emerald Medical Applications Ltd, a private Israeli company ("Emerald"), pursuant to which the Company agreed to loan Emerald the principal sum of US$90,000 (the "Loan"). There were no other material subsequent events following the period ended December, 31, 2014 and throughout the date of the filing of Form 10-K.

Note 11. Subsequent Events

9 Months Ended

12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Note 11. Subsequent Events

Between November 5 to November 9, 2015, 255,750 Shares were issued for services.

On November 9, 2015 a claim was filed to the Tel Aviv, Israel court against the Company and its wholly owned subsidiary for payment of past due fees by its former counsel.

Note 7. Subsequent Events.

During January 2015, the Company issued 750,000 restricted units each consisting of one share of common stock, par value $0.0001 ("Common Stock") and one warrant to purchase one additional share of Common Stock (the "Units") at a post-reverse price of US$0.40 per units. The sales were made without registration under the Securities Act of 1933, as amended (the "Act") in reliance upon the exemptions provided in Section 4(2) of the Act and Regulation S promulgated by the United States Securities and Exchange Commission (the "SEC") under the Act.

On February 2, 2015, the Company entered into a Loan Agreement with Emerald Medical Applications Ltd, a private Israeli company ("Emerald"), pursuant to which the Company agreed to loan Emerald the principal sum of US$90,000 (the "Loan").

There were no other material subsequent events following the period ended December, 31, 2014 and throughout the date of the filing of Form 10-K.